Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, Olema reports key information about its operations, financing activities, and clinical programs through forms such as 8-K, as well as registration statements and prospectus supplements.
Recent Olema 8-K filings include disclosures about an underwritten public offering of common stock conducted under an effective shelf registration statement on Form S-3, the termination of an at-the-market (ATM) prospectus under a sales agreement with TD Securities (USA) LLC, and clinical collaboration agreements with Pfizer to evaluate palazestrant plus atirmociclib in ER+/HER2- metastatic breast cancer. Other 8-Ks furnish press releases reporting quarterly financial results and updated data from Phase 1b/2 studies of palazestrant in combination with ribociclib in advanced or metastatic ER+/HER2- breast cancer.
Through Olema’s SEC filings, investors can review details of its capital-raising transactions, such as the size and terms of public offerings, the use of shelf registration statements on Form S-3, and the structure of underwriting agreements. Filings also identify the company’s registered securities, including its common stock listed under the symbol OLMA on The Nasdaq Global Select Market.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand material events, financial updates, and clinical or collaboration disclosures. Users can monitor new 8-Ks and other SEC reports in real time, track changes related to Olema’s clinical-stage oncology programs, and reference historical filings to follow the evolution of its palazestrant and OP-3136 pipelines and financing history.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company advancing palazestrant (OP-1250) and a KAT6 inhibitor (OP-3136). At June 30, 2025 the company reported total cash, cash equivalents and marketable securities of $361.9 million (cash and cash equivalents of $52.5 million and marketable securities of $309.4 million) and an available balance of $22.0 million under its loan agreement; management states this liquidity is sufficient to fund the current operating plan for at least the next 12 months. Total assets were $382.0 million with stockholders' equity of $345.2 million.
For the quarter ended June 30, 2025, Olema recorded a net loss of $43.8 million (loss per share $0.51); for the six months the net loss was $74.2 million (loss per share $0.87). Research and development expense was $43.9 million for the quarter and $74.5 million for six months, which included a $10.0 million one-time milestone to Aurigene. The company drew $3.0 million under its Credit Facility and continues collaborations with Novartis and Pfizer to supply CDK4/6 inhibitors for clinical trials; it completed a 2024 private placement that generated approximately $237.0 million net proceeds and maintains an at-the-market program with $150.0 million capacity.
Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.
The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.